www.proactiveinvestors.com.au

www.proactiveinvestors.com.au
Share

www.proactiveinvestors.com.au

 •  October 19, 2017

Pharmaxis (ASX:PXS) has made several key appointments to further strengthen its capability in drug discovery and development. Following a global search, Dr Dieter Hamprecht has been appointed as the head of chemistry in the Pharmaxis drug discovery team. The company’s drug discovery track record is strong having generated five lead candidates s in...

www.proactiveinvestors.com.au

 •  August 24, 2017

Noxopharm Ltd (ASX:NOX) has geared up to accelerate the development of its front-line anti-cancer drug NOX66, after raising $5.5 million via the placement of shares at $0.33 each. The company has raised the funds from sophisticated and institutional investors to fast-track the clinical development of NOX66, currently undergoing clinical...

www.proactiveinvestors.com.au

 •  May 10, 2017

Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI). CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics. IMM-529 is a biological product which is intended to...

www.proactiveinvestors.com.au

 •  February 14, 2017

Benitec Biopharma (ASX:BLT) has entered into an agreement with Maryland-based Omnia Biologics to manufacture material for its current first-in-man clinical trial for its TT-034 hepatitis C treatment. This ensures the company has enough clinical material to complete the current trial. The company is also moving to establish its own scalable...